Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 3.5% – What’s Next?

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) were up 3.5% during mid-day trading on Friday . The stock traded as high as $0.28 and last traded at $0.26. Approximately 29,962,066 shares traded hands during trading, a decline of 57% from the average daily volume of 68,989,281 shares. The stock had previously closed at $0.26.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on Tonix Pharmaceuticals in a research note on Thursday. They issued a “hold” rating for the company.

Tonix Pharmaceuticals Stock Performance

The company has a market cap of $52.09 million, a PE ratio of -0.01 and a beta of 2.02. The stock’s 50 day simple moving average is $0.25 and its two-hundred day simple moving average is $0.32. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. The firm had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. As a group, research analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.